Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2021-001280-24-LT
EUCTR2021-001280-24-LTActive, not recruitingPhase 1

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis

Vedanta Biosciences, Inc.0 sites100 target enrollmentStarted: August 19, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
100
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Able and willing to provide written informed consent prior to initiation of any study specific procedure or drug administration and understands the potential risks and benefits of study enrollment and study drug administration. When appropriate, informed consent may be provided by a legally authorized representative (LAR).
  • •2. 18 to 75 years of age.
  • •3. Documented clinical and endoscopic diagnosis of UC at least 3 months prior to randomization
  • •4. Active mild to moderate UC, as defined by the following:
  • •a. Disease that extends at least 15 cm from the anal verge
  • •b. A modified Mayo score of 4 to 8 with:
  • •i. Mayo endoscopic subscore of = 2 based on screening flexible sigmoidoscopy
  • •ii. Rectal bleeding score of = 1
  • •5. Is up to date with current local colorectal cancer surveillance recommendations (eg, has had a surveillance colonoscopy within 12 months if indicated based on extent and duration of UC); this may be performed during screening.
  • •6. Has never received a biologic agent, Janus kinase inhibitor, or sphingosine-1-phosphate modulators for the treatment of UC
  • •7. If receiving corticosteroids, dose must be stable for at least 4 weeks and be no higher than 10 mg QD prednisone (or prednisone equivalent) or budesonide 9 mg QD.
  • •8. Doses of other allowable UC medications (see Section 8.2.2 for details) must be stable for at least 8 weeks before randomization.
  • •9. If a female patient (according to sex assignment at birth):
  • •- Is not of childbearing potential, defined as post-menopausal for at least 1 year or surgically sterile due to hysterectomy, bilateral oophorectomy, or bilateral tubal ligation
  • •- If of childbearing potential, must have a negative pregnancy test and agree to either remain celibate or use a highly effective form of birth control (as defined in Appendix 1) from the time of enrollment until 3 months after the last dose of study drug
  • •- Agrees not to donate eggs (ova, oocytes) for purposes of assisted reproduction from the time of enrollment until 3 months after the last dose of study drug
  • •- Is not breastfeeding
  • •10. If a male patient (according to sex assignment at birth):
  • •- If not vasectomized, agrees to wear a condom when engaging in sexual intercourse with any partner of childbearing potential from the time of enrollment until 3 months after the last dose of study drug
  • •- Agrees not to donate sperm for purpose of reproduction from the time of enrollment until 3 months after the last dose of study drug
  • •11. Able and willing to follow study procedures (eg, comply with study visits and procedures, provide blood and stool samples).
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 75
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 25

Exclusion Criteria

  • •1. Known history of CD or indeterminate colitis
  • •2. A known diagnosis of primary sclerosing cholangitis
  • •3. Allergy to VE202 or any of its components (Section 9.1.1)
  • •4. Allergy to vancomycin or any of its components (Section 9.2)
  • •5. A diagnosis of any non-IBD diarrheal illness (eg, Clostridioides difficile, celiac disease, parasitic infection) within 3 months prior to randomization
  • •6. Known or suspected toxic megacolon, abdominal abscess, and/or small bowel ileus at the time of screening
  • •7. Any other anatomic or medical contraindication to flexible sigmoidoscopy
  • •8. Evidence of an active infection
  • •9. Recent fever, defined as > 38.0 °C (rectal equivalent) within 3 days prior to randomization
  • •10. Receipt of FMT or other fecal-derived preparation within 6 months prior to randomization
  • •11. Use of systemic or non-absorbable oral antibiotics within the prior 4 weeks before randomization or anticipated within the study period
  • •12. Use of probiotics within the prior 2 weeks before randomization (consumption of food products such as yogurt, kombucha, kimchi, and kefir is permissible)
  • •13. Receipt of herbal, botanical, or traditional medicinal preparations within the 2 weeks prior to randomization (consumption of mint, turmeric, or other herbal teas is permissible)
  • •14. Active drug or alcohol abuse
  • •15. Active colonic dysplasia
  • •16. Presence of adenomatous polyp on screening endoscopy, or history of adenomatous polyps that were not removed
  • •17. Prior colectomy, ostomy, or other intestinal surgery (excluding cholecystectomy or appendectomy)
  • •18. Active malignancy within the 2 years prior to randomization, with the exception of non-melanoma skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has been treated with local excision for curative intent
  • •19. For female patients (according to sex assignment at birth), expectation of pregnancy or lactation during the study period
  • •20. Receipt of any investigational drug or vaccine within the 30 days prior to randomization
  • •21. Receipt of any investigational biologic within 60 days or 5 half-lives prior to randomization, whichever is longer
  • •22. Aspartate aminotransferase or alanine aminotransferase levels > 3×ULN
  • •23. Total or direct bilirubin > 1.5×ULN or direct-to-total bilirubin ratio > 0.5
  • •24. Evidence of decompensated cirrhosis
  • •25. Serum albumin < 3.0 g/dL
  • •26. Known active hepatitis B or hepatitis C, or any positive laboratory result consistent with active disease (eg, hepatitis B surface antigen, hepatitis C antibody [unless patient has a history of treatment with successful resolution and an undetectable viral load])
  • •27. Known human immunodeficiency virus infection or other serious congenital or acquired immunodeficiency
  • •28. Absolute neutrophil count < 1000/µL
  • •29. Serum creatinine > 2×ULN or calculated creatine clearance < 30 mL/min
  • •30. Inability or unwillingness to comply with protocol requirements
  • •31. Any other active or poorly controlled comorbid condition that, in the opinion of the Investigator, may be expected to interfere with either study compliance or interpretation of study results

Investigators

Similar Trials

Active, not recruiting
Phase 3
Study to evaluate the long-term safety and efficacy of the investigational drug LIB003 for the reduction of cholesterol in patients with Heterozygous Familial Hypercholesterolemia
CTRI/2022/01/039679IB Therapeutics LLC
Active, not recruiting
Phase 1
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients With Cardiovascular Disease.Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol ReductionMedDRA version: 20.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849
EUCTR2020-004392-40-DEIB Therapeutics, LLC900
Active, not recruiting
Phase 1
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCAAssociated Vasculitis (AAV).Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitisMedDRA version: 21.1Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 20.1Level: PTClassification code 10050894Term: Anti-neutrophil cytoplasmic antibody positive vasculitisSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 21.1Level: PTClassification code 10072579Term: Granulomatosis with polyangiitisSystem Organ Class: 10047065 - Vascular disorders
EUCTR2016-001121-14-ITCHEMOCENTRYX, INC.331
Active, not recruiting
Not Applicable
Randomized, Double-Blind, Placebo-Controlled, Phase 2Study of Gemcitabine and Cisplatin Plus Enzastaurinversus Gemcitabine and Cisplatin Plus Placebo,Followed by Maintenance Enzastaurin or Placebo inChemonaive Patients with Advanced, Unresectable, orMetastatic (Stage IIIB or IV) Non-Small Cell Lung Cancer - ND
EUCTR2006-005306-31-ITELI LILLY120
Active, not recruiting
Phase 1
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients With Cardiovascular Disease.Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol ReductionMedDRA version: 20.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849
EUCTR2020-004392-40-NOIB Therapeutics, LLC900